MedTrace Logo

Evaluation of Customized Treatment According to BRCA1 Assessment in Patients With Advanced Gastric Cancer

NCT01206218 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2010-09-21

No results posted yet for this study

Summary

Evaluation of customized treatment according to BRCA1 assessment in patients with advanced gastric cancer

Conditions

  • Advanced Gastric Cancer

Interventions

DRUG

FLOT Regimen

FLOT Regimen: 5-fluorouracil, Oxaliplatin, Docetaxel

DRUG

FLO Regimen or FLOT Regimen

FLO Regimen: 5-fluorouracil, Oxaliplatin FLOT Regimen: 5-fluorouracil, Oxaliplatin, Docetaxel

Sponsors & Collaborators

  • The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

    lead OTHER

Principal Investigators

  • Baorui Liu, MD, PHD · Drum Tower Hospital, Nanjing University Medical School

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2012-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01206218 on ClinicalTrials.gov